2-{4-[4-(acetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine | 862683-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-{4-[4-(acetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine
• 英文别名: 1-[4-[4-[[5-fluoro-4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone
• CAS: 862683-97-4
• 化学式: C₂₃H₂₈FN₇O
• 分子量: 437.52
• InChiKey: IEYSBUGVOQJGPT-UHFFFAOYSA-N

物化性质

• 沸点：
  703.9±70.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-{4-[4-(acetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine 在 盐酸 、 水 、 异丙醇 作用下， 以91%的产率得到2-{4-[4-piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine
  参考文献：
  名称：

  Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode

  摘要：

  A piperazine series of cyclin-dependent kinase (CDK) inhibitors have been identified. The compounds exhibit excellent physiochemical properties and a novel binding mode, whereby a bridging interaction via a water molecule with Asp 86 of CDK2, leads to selectivity for the CDK family of enzymes over other kinases. Piperazines 2e and 2i were subsequently shown to inhibit tumour growth when dosed orally in a nude mouse xenograft study. Additional chemical series that exploit this unexpected interaction with Asp 86 are also described.

  DOI：

  10.1016/j.bmcl.2008.06.027
• 作为产物：
  描述：

  (2Z)-3-(dimethylamino)-2-fluoro-1-(1-isopropyl-2-methyl-1H-imidazol-5-yl)prop-2-en-1-one 、 N-[4-(4-acetylpiperazin-1-yl)phenyl]guanidine bicarbonate salt 以 乙二醇甲醚 为溶剂， 反应 18.0h， 以81%的产率得到2-{4-[4-(acetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine
  参考文献：
  名称：

  [EN] IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION
  [FR] IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES UTILISES EN TANT QU'AGENTS INHIBITEURS DE LA PROLIFERATION CELLULAIRE

  摘要：

  化合物的公式（I），其中变量基团的定义如内部，并描述了药用盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效果的药物。

  公开号：

  WO2005075461A1

文献信息

• Chemical compounds
  申请人：Andrews Michael David

  公开号：US20070161615A1

  公开（公告）日：2007-07-12

  Compounds of the formula (I), wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.

  本文描述了公式（I）的化合物，其中变量基团的定义如内部所述，并描述了药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生细胞周期抑制（抗细胞增殖）效果的药物，用于温血动物，如人类。
• Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
  申请人：AstraZeneca AB

  公开号：US07655652B2

  公开（公告）日：2010-02-02

  Compounds of the formula (I), wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.

  本文描述了公式（I）的化合物，其中可变的基团在定义范围内，并且是药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效果的药物。
• IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION
  申请人：AstraZeneca AB

  公开号：EP1748999A1

  公开（公告）日：2007-02-07
• US7655652B2
  申请人：——

  公开号：US7655652B2

  公开（公告）日：2010-02-02
• Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode
  作者：M. Raymond V. Finlay、David G. Acton、David M. Andrews、Andrew J. Barker、Michael Dennis、Eric Fisher、Mark A. Graham、Clive P. Green、David W. Heaton、Galith Karoutchi、Sarah A. Loddick、Rémy Morgentin、Andrew Roberts、Julie A. Tucker、Hazel M. Weir

  DOI：10.1016/j.bmcl.2008.06.027

  日期：2008.8

  A piperazine series of cyclin-dependent kinase (CDK) inhibitors have been identified. The compounds exhibit excellent physiochemical properties and a novel binding mode, whereby a bridging interaction via a water molecule with Asp 86 of CDK2, leads to selectivity for the CDK family of enzymes over other kinases. Piperazines 2e and 2i were subsequently shown to inhibit tumour growth when dosed orally in a nude mouse xenograft study. Additional chemical series that exploit this unexpected interaction with Asp 86 are also described.